<DOC>
	<DOCNO>NCT01295086</DOCNO>
	<brief_summary>The primary aim dose-finding study determine maximum tolerate dose taxotere , eloxatin capecitabine ( TEX ) combination herceptin give every third week first-line treatment patient HER2-positive advanced gastro-esophageal cancer . Secondary end point evaluate progression-free survival overall survival .</brief_summary>
	<brief_title>Taxotere® , Eloxatin® Xeloda® ( TEX ) Combination With Herceptin® Treatment HER2 Positive Non-resectable Cancer</brief_title>
	<detailed_description>Primary aim : To define maximum tolerate dose combination taxotere , eloxatin capecitabine ( TEX ) combination herceptin give every third week first- line treatment patient HER2-positive advanced gastro-esophageal cancer . Secondary aim : Estimating response-rate , progression free survival overall survival Methods : This dose-finding study plan include 15 patient HER2 positive gastro-esophageal cancer , adenocarcinoma . Patients include cohort three progressively high dose level . Chemotherapy repeat day 1 every third week maximum eight cycle . Treatment trastuzumab continue disease progression . Dose-limiting toxicity ( DLT ) evaluate first cycle . In case DLT among one three patient first course treatment additional three patient add respective dose level . Dose escalation continue 0/3 1/6 patient experience DLT . Patients evaluate ct- scan baseline every three cycle exclude progression evaluate response . Response assess investigator accord RECIST version 1.1 . Blood count regard tumour biology collect baseline 2nd , 4th 7th cycle 4 week end treatment . After completion treatment patient follow every third month progression death .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Patients histologically proven ECVadenocarcinoma , nonresectable metastatic disease 2 . HER2positive tumor tissue ( IHC 3 + FISH positive ) 3 . LVEF &gt; 50 % ( MUGA scan echocardiography ) 4 . Age ≥ 18 year 5 . No prior chemotherapy 6. WHO performance status 01 7 . Life expectancy least 3 month 8 . Neutrophils ≥ 1.5 x 109/L platelet ≥ 100 x 109/L 9 . Bilirubin ≤ 1.5 x UNL ( Upper Normal Limit ) ASAT and/or ALAT ≤ 3 x UNL . In case liver metastasis UNL ASAT ALAT 10 . Creatinine clearance ≥ 50 ml/min . Calculated CockroftGault formula 11 . No neuropathy 12 . Planned treatment start within 8 day inclusion 1 . Patients complete treatment evaluation 2 . Any condition treatment opinion investigator may expose patient risc influence purpose study 3 . Known hypersensitivity towards study drug 4 . Other malignant disease within last 5 day , except nonmelanoma skin cancer 5 . Other serious disease ( e.g . cardiac disease , AMI within 1 year infection ) 6 . Pregnant woman nurse woman 7 . Physical mental condition may prevent absorption oral treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Adenocarcinoma gastro-esophageal</keyword>
	<keyword>Her2</keyword>
	<keyword>Dose find</keyword>
	<keyword>Taxotere ( Docetaxel )</keyword>
	<keyword>Eloxatin ( Oxaliplatin )</keyword>
	<keyword>Xeloda ( Capecitabine )</keyword>
	<keyword>Herceptin ( Trastuzumab )</keyword>
</DOC>